| Autor: |
Rabab M. A. Mahmoud, Amr Mohammed Shaker, Khaled Marzouk Sadek, May Hassaballa, Mervat Mohammed El-Ansari, Mohammed Saadi, Tarek Fayad |
| Rok vydání: |
2016 |
| Předmět: |
|
| Zdroj: |
Journal of The Egyptian Society of Nephrology and Transplantation. 16:119 |
| ISSN: |
1110-9165 |
| Popis: |
Aim Phospholipase A2 receptor (PLA2R) in the past few years has been identified as an antigenic target in idiopathic membranous nephropathy (IMN). The question remains, however, whether the diagnostic and prognostic values of anti-phospholipase A2 receptor (APLA2R) antibodies apply to patients with IMN who are of different ethnicities. The aim of this research was to assess the prevalence of APLA2R antibodies in Egyptian patients with IMN and to describe the clinical importance of measuring APLA2R antibodies in those patients. Patients and methods Using an indirect immunofluorescence (IF) assay, we measured APLA2R antibodies level in 30 patients with IMN in Egypt (three samples/patient). Patients were divided in two groups: group 1 included 15 consecutive patients at the time of diagnosis and group 2 included 15 consecutive patients during their remission or relapse period. Results APLA2R antibodies were detected in 40% of the patients in both groups equally. Overall, 68% of them had a nephrotic-range proteinuria (P=0.002). The titer ranged from 1 : 10 to 1 : 40. The reactive patients had significantly lower serum albumin levels at the presentation (P=0.049), and the average time to remission for them was longer in comparison with the nonreactive patients. Conclusion In our study, APLA2R antibodies were found in 40% of the patients. It correlates with the disease activity regarding remission and relapse, and its reactivity was higher in more severe disease. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
